A Phase I Study of Everolimus plus Standard Chemotherapy for Patients with T-Cell Lymphoblastic Leukemia or Lymphoma

Full Title

ENCERT: A Phase 1 Trial using Everolimus in combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia/Lymphoma

Purpose

The purpose of this study is to find the highest dose of the drug everolimus that can be given safely with standard chemotherapy in children and young adults with T-cell lymphoblastic leukemia or lymphoma that continues to grow or came back despite prior therapy. Everolimus is already used to treat several types of cancer; its use in this study is considered investigational.

Everolimus works by blocking a cell signaling pathway called mTOR that cancer cells use to grow and survive. Blocking this pathway can slow the growth of cancer cells and stop the signals that contribute to cancer development. Everolimus is taken orally (by mouth); patients will also receive intravenous chemotherapy drugs (given by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• This study is for patients older than age 1 year and younger than 30.
• Patients must have T-cell lymphoblastic leukemia or lymphoma that continues to grow or came back despite prior therapy.

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.